Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RO7673396 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Stage I | EXPERIMENTAL | Participants with advanced solid tumors harboring RAS mutations will receive multiple ascending doses of RO7673396, as per a pre-defined dosing regimen until unacceptable toxicity or disease progression (PD) and/or loss of clinical benefit as determined by the investigator. |
| Stage II | EXPERIMENTAL | Participants with advanced solid tumors harboring RAS mutations will receive RO7673396 at the dose determined in Stage 1, until unacceptable toxicity or PD and/or loss of clinical benefit as determined by the investigator. |
| Name | Type | Description |
|---|---|---|
| RO7673396 | DRUG | RO7673396 will be administered as per the schedule specified in the protocol. |
Inclusion Criteria: * Histologically documented, locally advanced, recurrent, or metastatic incurable solid tumors * Participants with measurable disease according to RECIST v1.1 assessed by the investigator * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Life expectancy ...
Top 14 of 16 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | Luspatercept, Fedratinib, BMS-986158 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, ABBV-744, IMGN632 |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 2 | PHASE3 | Elritercept |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Incyte Corporation | INCY | 8 | PHASE2 | Ruxolitinib, INCB160058, INCB057643, INCA033989, INCA036978 |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| GSK plc Sponsored ADR | GSK | 3 | PHASE2 | Momelotinib |
| Eli Lilly and Company | LLY | 2 | PHASE1 | LY3410738, LY5830966 |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Damora Therapeutics, Inc. | DMRA | 2 | PHASE2 | GB2064, DMR-001 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| Syndax Pharmaceuticals Inc | SNDX | 1 | PHASE1 | Revumenib |
RO7673396 is an investigational small molecule being studied for the treatment of advanced solid tumors that harbor RAS mutations. It is in Phase 1 clinical development in oncology and has not been approved for any indication. The trial enrolls adults with advanced solid tumors whose tumors carry a RAS mutation.
RO7673396 is being developed by Roche Holding AG, which trades on the OTC market under the ticker RHHBY. Roche is the sponsor of the Phase 1 clinical program evaluating the compound in patients with advanced solid tumors harboring RAS mutations.
RO7673396 is in Phase 1 clinical development. It is an investigational agent and has not been approved by the FDA or any other regulatory authority. The single ongoing Phase 1 trial is currently recruiting participants and is designed to evaluate safety, tolerability, pharmacokinetics, and preliminary clinical activity.
RO7673396 is being evaluated in one active Phase 1 trial, NCT06884618, titled a study to evaluate the safety, tolerability, pharmacokinetics, and preliminary clinical activity of RO7673396 in participants with advanced solid tumors harboring RAS mutations. The trial is recruiting and plans to enroll 405 participants across the United States, Australia, Canada, China, Denmark, Hong Kong, New Zealand, Singapore, Spain, Taiwan, and the United Kingdom.
RO7673396 targets RAS-mutant tumors. The Phase 1 trial NCT06884618 specifically enrolls patients with advanced solid tumors harboring rat sarcoma viral oncogene homolog (RAS) mutations, indicating that the compound is designed to address cancers driven by RAS mutations. It is a small molecule therapeutic.